Blockade of TGF-β signaling: a potential target for cancer immunotherapy?

References

• Flavell RA, Sanjabi S, Wrzesinski SH, et al. The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol. 2010;10:554–567.
   PubMed Web of Science ®Google Scholar
• Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014;32:51–82.
   PubMed Web of Science ®Google Scholar
• Yang Z, Mu Z, Dabovic B, et al. Absence of integrin-mediated TGFβ1 activation in vivo recapitulates the phenotype of TGFβ1-null mice. J Cell Biol. 2007;176:787–793.
   PubMed Web of Science ®Google Scholar
• Travis MA, Reizis B, Melton AC, et al. Loss of integrin α(v)β8 on dendritic cells causes autoimmunity and colitis in mice. Nature. 2007;449:361–365.
   PubMed Web of Science ®Google Scholar
• Worthington JJ, Czajkowska BI, Melton AC, et al. Intestinal dendritic cells specialize to activate transforming growth factor-β and induce Foxp3+ regulatory T cells via integrin αvβ8. Gastroenterology. 2011;141:1802–1812.
   PubMed Web of Science ®Google Scholar
• Edwards JP, Thornton AM, Shevach EM. Release of active TGF-β1 from the latent TGF-β1/GARP complex on T regulatory cells is mediated by integrin β8. J Immunol. 2014;193:2843–2849.
   PubMed Web of Science ®Google Scholar
• Worthington JJ, Kelly A, Smedley C, et al. Integrin αvβ8-mediated TGF-β activation by effector regulatory T cells is essential for suppression of T-cell-mediated inflammation. Immunity. 2015;42:903–915.
   PubMed Web of Science ®Google Scholar
• Mu Y, Gudey SK, Landstrom M. Non-Smad signaling pathways. Cell Tissue Res. 2012;347(1):11–20.
   PubMed Web of Science ®Google Scholar
• David CJ, Massague J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):479.
   PubMed Web of Science ®Google Scholar
• Ayyaz A, Attisano L, Wrana JL. Recent advances in understanding contextual TGFβ signaling. F1000Res. 2017;6:749.
   PubMedGoogle Scholar
• Ungefroren H. TGF-β signaling in cancer: control by negative regulators and crosstalk with proinflammatory and fibrogenic pathways. Cancers (Basel). 2019;11(3):E384.
   PubMed Web of Science ®Google Scholar
• Massague J. TGFβ in Cancer. Cell. 2008;134:215–230.
   PubMed Web of Science ®Google Scholar
• Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3:56–71.
   PubMed Web of Science ®Google Scholar
• Seoane J. Escaping from the TGFβ anti-proliferative control. Carcinogenesis. 2006;27(11):2148–2156.
   PubMed Web of Science ®Google Scholar
• Tian M, Neil JR, Schiemann WP. Transforming growth factor-β and the hallmarks of cancer. Cell Signal. 2011;23:951–962.
   PubMed Web of Science ®Google Scholar
• Calon A, Lonardo E, Berenguer-Llergo A. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47:320–329.
   PubMed Web of Science ®Google Scholar
• Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571–584.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48:812–830.
   PubMed Web of Science ®Google Scholar
• Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-β: from conception to autoimmunity and infection. Cold Spring Harb Perspect Biol. 2017;9:a022236.
   PubMed Web of Science ®Google Scholar
• Dahmani A, Delisle JS. TGF-β in T cell biology: implications for cancer immunotherapy. Cancers (Basel). 2018;10(6):E194.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Beckett O, Ma Q, et al. Transforming growth factor-β signaling curbs thymic negative selection promoting regulatory T cell development. Immunity. 2010;32:642–653.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171–181.
   PubMed Web of Science ®Google Scholar
• Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-β and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity. 2009;31:131–144.
   PubMed Web of Science ®Google Scholar
• Filippi CM, Juedes AE, Oldham JE, et al. Transforming growth factor-β suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: A two-faced impact on autoimmunity. Diabetes. 2008;57:2684–2692.
   PubMed Web of Science ®Google Scholar
• Guan T, Dominguez CX, Amezquita RA, et al. ZEB1, ZEB2, and the miR-200 family form a counterregulatory network to regulate CD8(+) T cell fates. J Exp Med. 2018;215:1153–1168.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–548.
   PubMed Web of Science ®Google Scholar
• Patel SA, Meyer JR, Greco SJ, et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol. 2010;184(10):5885–5894.
   PubMed Web of Science ®Google Scholar
• Kuczek DE, Larsen AMH, Thorseth ML, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7(1):68.
   PubMed Web of Science ®Google Scholar
• Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163:1037–1050.
   PubMed Web of Science ®Google Scholar
• Donkor MK, Sarkar A, Li MO. TGF-β1 produced by activated CD4(+) T cells antagonizes T cell surveillance of tumor development. Oncoimmunology. 2012;1:162–171.
   PubMed Web of Science ®Google Scholar
• Shi C, Chen Y, Chen Y, et al. CD4+ CD25+ regulatory T cells promote hepatocellular carcinoma invasion via TGF-β1-induced epithelial-mesenchymal transition. Onco Targets Ther. 2018;12:279–289.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-β inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol. 2000;165:4773–4777.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation. J Exp Med. 2002;195:1499–1505.
   PubMed Web of Science ®Google Scholar
• Lin JT, Martin SL, Xia L, et al. TGF-β 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet. J Immunol. 2005;174:5950–5958.
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–1886.
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004;172:5149–5153.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang P, Li J, et al. A critical function for TGF-β signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol. 2008;9:632–640.
   PubMed Web of Science ®Google Scholar
• Liénart S, Merceron R, Vanderaa C, et al. Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells. Science. 2018;362(6417):952–956.
   PubMed Web of Science ®Google Scholar
• Cuende J, Liénart S, Dedobbeleer O, et al. Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci Transl Med. 2015;7(284):284ra56.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51.
   PubMed Web of Science ®Google Scholar
• Chaput N, Louafi S, Bardier A, et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut. 2009;58:520–529.
   PubMed Web of Science ®Google Scholar
• Wang A, Pan D, Lee YH, et al. Cutting edge: smad2 and Smad4 regulate TGF-β-mediated IL9 gene expression via EZH2 displacement. J Immunol. 2013;191(10):4908–4912.
   PubMed Web of Science ®Google Scholar
• Zhang S. The role of transforming growth factor β in T helper 17 differentiation. Immunology. 2018 Sep;155(1):24–35.
   PubMed Web of Science ®Google Scholar
• Skon CN, Lee JY, Anderson KG, et al. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat Immunol. 2013;14(12):1285–1293.
   PubMed Web of Science ®Google Scholar
• Mackay LK, Wynne-Jones E, Freestone D, et al. T-box transcription factors combine with the cytokines TGF-β and IL-15 to control tissue-resident memory T cell fate. Immunity. 2015;43(6):1101–1111.
   PubMed Web of Science ®Google Scholar
• Zhou L, Lopes JE, Chong MM, et al. TGF-β-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008;453:236–240.
   PubMed Web of Science ®Google Scholar
• Hasan M, Neumann B, Haupeltshofer S, et al. Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation. Immunol Cell Biol. 2015;93:662–672.
   PubMed Web of Science ®Google Scholar
• Hahn JN, Falck VG, Jirik FR. Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. J Clin Investig. 2011;121:4030–4042.
   PubMed Web of Science ®Google Scholar
• Zhang S, Takaku M, Zou L, et al. Reversing SKI-SMAD4-mediated suppression is essential for Th17 cell differentiation. Nature. 2017;551:105–109.
   PubMed Web of Science ®Google Scholar
• Takai S, Schlom J, Tucker J, et al. Inhibition of TGF-β1 signaling promotes central memory T cell differentiation. J Immunol. 2013;191(5):2299–2307.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121–1133.
   PubMed Web of Science ®Google Scholar
• Lucas PJ, Kim SJ, Melby SJ, et al. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β II receptor. J Exp Med. 2000;191:1187–1196.
   PubMed Web of Science ®Google Scholar
• Zhang N, Bevan MJ. TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat Immunol. 2012;13:667–673.
   PubMed Web of Science ®Google Scholar
• Wolfraim LA, Walz TM, James Z, et al. p21Cip1 and p27Kip1 act in synergy to alter the sensitivity of naive T cells to TGF-β-mediated G1 arrest through modulation of IL-2 responsiveness. J Immunol. 2004;173:3093–3102.
   PubMed Web of Science ®Google Scholar
• Li L, Iwamoto Y, Berezovskaya A, et al. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol. 2006;7:1157–1165.
   PubMed Web of Science ®Google Scholar
• Ruegemer JJ, Ho SN, Augustine JA, et al. Regulatory effects of transforming growth factor-β on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol. 1990;144:1767–1776.
   PubMed Web of Science ®Google Scholar
• Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. Embo J. 1999;18:1280–1291.
   PubMed Web of Science ®Google Scholar
• Delisle JS, Giroux M, Boucher G, et al. The TGF-β-Smad3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells. Genes Immun. 2013;14:115–126.
   PubMed Web of Science ®Google Scholar
• McKarns SC, Schwartz RH. Distinct effects of TGF-β 1 on CD4+ and CD8+ T cell survival, division, and IL-2 production: A role for T cell intrinsic Smad3. J Immunol. 2005;174:2071–2083.
   PubMed Web of Science ®Google Scholar
• Chen CH, Seguin-Devaux C, Burke NA, et al. Transforming growth factor β blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med. 2003;197:1689–1699.
   PubMed Web of Science ®Google Scholar
• Park BV, Freeman ZT, Ghasemzadeh A, et al. TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. 2016;6:1366–1381.
   PubMed Web of Science ®Google Scholar
• Choudhry MA, Sir O, Sayeed MM. TGF-β abrogates TCR-mediated signaling by upregulating tyrosine phosphatases in T cells. Shock. 2001;15:193–199.
   PubMed Web of Science ®Google Scholar
• Giroux M, Delisle JS, O’Brien A, et al. T cell activation leads to protein kinase C theta-dependent inhibition of TGF-β signaling. J Immunol. 2010;185:1568–1576.
   PubMed Web of Science ®Google Scholar
• Arumugam V, Bluemn T, Wesley E, et al. TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β. J Leukoc Biol. 2015;98(5):703–712.
   PubMed Web of Science ®Google Scholar
• Cottrez F, Groux H. Regulation of TGF-β response during T cell activation is modulated by IL-10. J Immunol. 2001;167:773–778.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massague J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369–380.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med. 2001;7:1118–1122.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol. 2005;174:5215–5223.
   PubMed Web of Science ®Google Scholar
• Lin R, Chen L, Chen G, et al. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Investig. 2014;124:5352–5367.
   PubMed Web of Science ®Google Scholar
• Komdeur FL, Prins TM, van de Wall S, et al. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology. 2017;6(9):e1338230.
   PubMed Web of Science ®Google Scholar
• Djenidi F, Adam J, Goubar A, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194(7):3475–3486.
   PubMed Web of Science ®Google Scholar
• Zloza A, Jagoda MC, Lyons GE, et al. CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression. Cancer Immunol Immunother. 2011;60(2):291–297.
   PubMed Web of Science ®Google Scholar
• Casetti R, Agrati C, Wallace M, et al. Cutting edge: TGF-β1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol. 2009;183:3574–3577.
   PubMed Web of Science ®Google Scholar
• Li X, Kang N, Zhang X, et al. Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the presence of TGF-β and their involvement in the pathogenesis of systemic lupus erythematosus. J Immunol. 2011;86(12):6693–6700.
   Web of Science ®Google Scholar
• Doisne JM, Bartholin L, Yan KP, et al. iNKT cell development is orchestrated by different branches of TGF-beta signaling. J Exp Med. 2009;206:1365–1378.
   PubMed Web of Science ®Google Scholar
• Havenar-Daughton C, Li S, Benlagha K, et al. Development and function of murine RORgammat+ iNKT cells are under TGF-beta signaling control. Blood. 2012;119:3486–3494.
   PubMed Web of Science ®Google Scholar
• Konkel JE, Maruyama T, Carpenter AC, et al. Control of the development of CD8alphaalpha+ intestinal intraepithelial lymphocytes by TGF-beta. Nat Immunol. 2011;12:312–319.
   PubMed Web of Science ®Google Scholar
• Viel S, Marcais A, Guimaraes FS, et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal. 2016;9:ra19.
   PubMed Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA. 2003;100:4120–4125.
   PubMed Web of Science ®Google Scholar
• Trotta R, Dal Col J, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181:3784–3792.
   PubMed Web of Science ®Google Scholar
• Marcoe JP, Lim JR, Schaubert KL, et al. TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol. 2012;13(9):843–850.
   PubMed Web of Science ®Google Scholar
• Gao Y, Souza-Fonseca-Guimaraes F, Bald T, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18:1004–1015.
   PubMed Web of Science ®Google Scholar
• Cortez VS, Cervantes-Barragan L, Robinette ML, et al. Transforming growth factor-β signaling guides the differentiation of innate lymphoid cells in salivary glands. Immunity. 2016;44:1127–1139.
   PubMed Web of Science ®Google Scholar
• Otegbeye F, Ojo E, Moreton S. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018;13(1):e0191358.
   PubMed Web of Science ®Google Scholar
• Novitskiy SV, Pickup MW, Chytil A, et al. Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties. J Leukoc Biol. 2012;92:641–651.
   PubMed Web of Science ®Google Scholar
• Jung NC, Lee JH, Chung KH, et al. Dendritic cell-based immunotherapy for solid tumors. Transl Oncol. 2018;11(3):686–690.
   PubMed Web of Science ®Google Scholar
• Melton AC, Bailey-Bucktrout SL, Travis MA, et al. Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Investig. 2010;120:4436–4444.
   PubMed Web of Science ®Google Scholar
• Barilla RM, Diskin B, Caso RC, et al. Specialized dendritic cells induce tumor-promoting IL-10+IL-17+ FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma. Nat Commun. 2019;10(1):1424.
   PubMed Web of Science ®Google Scholar
• Draghiciu O, Lubbers J, Nijman HW, et al. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology. 2015;4(1):e954829.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183–194.
   PubMed Web of Science ®Google Scholar
• Peng J, Tsang JY, Li D, et al. Inhibition of TGF-β signaling in combination with TLR7 ligation re-programs a tumoricidal phenotype in tumor-associated macrophages. Cancer Lett. 2013;331(2):239–249.
   PubMed Web of Science ®Google Scholar
• Jayaraman P, Parikh F, Newton JM, et al. TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. Oncoimmunology. 2018;7(10):e1490853.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Junca A, Driscoll KE, Pellicciotta I, et al. Autocrine TGFβ is a survival factor for monocytes and drives immunosuppressive lineage commitment. Cancer Immunol Res. 2019;7(2):306–320.
   PubMed Web of Science ®Google Scholar
• Diebold RJ, Eis MJ, Yin M, et al. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA. 1995;92(26):12215–12219.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Yaguchi T, Kawamura N, et al. TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression. J Immunother. 2014;37(2):63–72.
   PubMed Web of Science ®Google Scholar
• Donkor MK, Sarkar A, Savage PA, et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity. 2011;35:123–134.
   PubMed Web of Science ®Google Scholar
• Takasaka N, Seed RI, Cormier A, et al. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. JCI Insight. 2018;3(20):122591.
   PubMed Web of Science ®Google Scholar
• Díaz-Valdés N, Basagoiti M, Dotor J, et al. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res. 2011;71(3):812–821.
   PubMed Web of Science ®Google Scholar
• Gil-Guerrero L, Dotor J, Huibregtse IL, et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol. 2008;181(1):126–135.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu Z, Muranski P, et al. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 2013;20(5):575–580.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yang X, Pins M, et al. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005;65:1761–1769.
   PubMed Web of Science ®Google Scholar
• Foster AE, Dotti G, Lu A, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J Immunother. 2008;31:500–505.
   PubMed Web of Science ®Google Scholar
• Wang L, Wen W, Yuan J, et al. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor β-insensitive CD8+ T cells. Clin Cancer Res. 2010;16:164–173.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855–1866.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Helfand BT, Carneiro BA, et al. Efficacy against human prostate cancer by prostate-specific membrane antigen-specific, transforming growth factor-β insensitive genetically targeted CD8(+) T-cells derived from patients with metastatic castrate-resistant disease. Eur Urol. 2018;73:648–652.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Tripic T, Cruz CR, et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma. J Clin Oncol. 2018;36:1128–1139.
   PubMed Web of Science ®Google Scholar
• Principe DR, DeCant B, Mascariñas E, et al. TGFβ signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis. Cancer Res. 2016;76(9):2525–2539.
   PubMed Web of Science ®Google Scholar
• Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64(21):7954–7961.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Jung SM, Park SH, et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. EMBO Mol Med. 2013;5(11):1720–1739.
   PubMed Web of Science ®Google Scholar
• Hanks BA, Holtzhausen A, Evans KS, et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest. 2013;123(9):3925–3940.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–543.
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5(article):5241.
   PubMed Web of Science ®Google Scholar
• Sow HS, Ren J, Camps M, et al. Combined inhibition of TGF-β signaling and the PD-L1 immune checkpoint is differentially effective in tumor models. Cells. 2019;8(4):E320.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Schaer DA, Li Y, et al. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer. 2018;6(1):47.
   PubMed Web of Science ®Google Scholar
• Löffek S. Transforming of the tumor microenvironment: implications for TGF-β inhibition in the context of immune-checkpoint therapy. J Oncol. 2018;2018:9732939.
   PubMed Web of Science ®Google Scholar
• Garrison K, Hahn T, Lee WC, et al. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother. 2012;61:511–521.
   PubMed Web of Science ®Google Scholar
• Park J, Wrzesinski SH, Stern E, et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater. 2012;11:895–905.
   PubMed Web of Science ®Google Scholar
• Hutzen B, Chen CY, Wang PY, et al. TGF-β inhibition improves oncolytic herpes viroimmunotherapy in murine models of rhabdomyosarcoma. Mol Ther Oncolytics. 2017;7:17–26.
   PubMed Web of Science ®Google Scholar
• Courau T, Nehar-Belaid D, Florez L, et al. TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight. 2016;1:e85974.
   PubMed Web of Science ®Google Scholar
• Terabe M, Ambrosino E, Takaku S, et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody. Clin Cancer Res. 2009;15:6560–6569.
   PubMed Web of Science ®Google Scholar
• Kim S, Buchlis G, Fridlender ZG, et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res. 2008;68(24):10247–10256.
   PubMed Web of Science ®Google Scholar
• Ueda R, Fujita M, Zhu X, et al. Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res. 2009;15:6551–6559.
   PubMed Web of Science ®Google Scholar
• Takaku S, Terabe M, Ambrosino E, et al. Blockade of TGF-β enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J Cancer. 2010;126:1666–1674.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang Y, Zhang L, et al. Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano. 2014;8:3636–3645.
   PubMed Web of Science ®Google Scholar
• Terabe M, Robertson FC, Clark K, et al. Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncoimmunology. 2017;6:e1308616.
   PubMed Web of Science ®Google Scholar
• Soares KC, Rucki AA, Kim V, et al. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget. 2015;6(40):43005–43015.
   PubMedGoogle Scholar
• Pu N, Zhao G, Yin H, et al. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. J Transl Med. 2018;16(1):294.
   PubMed Web of Science ®Google Scholar
• Oettle H, Hilbig A, Seufferlein T, et al. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol. 2012;30(15_suppl):4034.
   Google Scholar
• Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy or high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2010;13(1):132–142.
   PubMed Web of Science ®Google Scholar
• Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (Fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014;9(3):e90353.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Takahashi H, Kondo S, et al. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2017;79(6):1169–1177.
   PubMed Web of Science ®Google Scholar
• Nizard M, Roussel H, Diniz MO, et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun. 2017;8:15221.
   PubMed Web of Science ®Google Scholar
• Fujii R, Jochems C, Tritsch SR, et al. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression. Cancer Immunol Immunother. 2018;67(4):675–689.
   PubMed Web of Science ®Google Scholar
• Zhu C, Shen H, Zhu L, et al. Plasminogen activator inhibitor 1 promotes immunosuppression in human non-small cell lung cancers by enhancing TGF-Β1 expression in macrophage. Cell Physiol Biochem. 2017;44(6):2201–2211.
   PubMedGoogle Scholar
• Zhu Y, Richardson JA, Parada LF, et al. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 1998;94:703–714.
   PubMed Web of Science ®Google Scholar
• Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287–1295.
   PubMed Web of Science ®Google Scholar
• Tang H, Wang Y, Chlewicki L, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;30(3):500.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–1022.
   PubMed Web of Science ®Google Scholar
• Chakravarthy A, Khan L, Bensler NP, et al. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9(1):4692.
   PubMed Web of Science ®Google Scholar